title: Complementary effect of oral administration of Lactobacillus paracasei K71 on canine atopic dermatitis.
abstract: BACKGROUND
  Atopic dermatitis is a common skin disease encountered in dogs. Glucocorticoids are commonly recommended for symptomatic therapy and well-tolerated adjunctive therapies may help to reduce the necessary dose and associated risks of chronic glucocorticoid use.
  
  
  OBJECTIVE
  The purpose of this study was to evaluate the complementary efficacy of oral administration of Lactobacillus paracasei K71 in canine atopic dermatitis (cAD).
  
  
  METHODS
  Forty one dogs with mild to moderate cAD were recruited by19 animal hospitals.
  
  
  METHODS
  Dogs were assigned to receive either the investigational agent (K71 group; n = 20) or cetirizine hydrochloride (control group; n = 21). Previously prescribed medications were allowed to be continued during the 12 week trial. Dogs were assessed by the investigators using the cAD Extent and Severity Index (CADESI) and a medication scoring system. Pet owners assessed their dogs using a visual analog scale (VAS) and pruritus scores.
  
  
  RESULTS
  The CADESI scores, VAS and pruritus scores in both groups at 12 weeks were improved compared with their baselines. The CADESI and pruritus scores in the K71 group were slightly lower than those in the control group and the reduction of medication scores in the K71 group was significantly lower compared with the control group (P < 0.05; Student's t-test).
  
  
  CONCLUSIONS
  Oral administration of K71 can be useful in dogs with cAD as a complementary therapy, by providing a steroid-sparing effect.
authors.affiliation: ASC Dermatology Service 1-3-2 Jindaijihigashi, Chofu, Tokyo, 182-0012, Japan.|Synergy Animal General Hospital Dermatology Service, 815 Ishigami Kawaguchi, Saitama, 333-0823, Japan.
authors.forename: Yuri
authors.initials: Y
authors.lastname: Ohshima-Terada
authors.affiliation: Kameda Seika Co., Ltd, 3-1-1 Kameda-Kogyodanchi Konan, Niigata, 950-0198, Japan.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Higuchi
authors.affiliation: Kameda Seika Co., Ltd, 3-1-1 Kameda-Kogyodanchi Konan, Niigata, 950-0198, Japan.
authors.forename: Takehisa
authors.initials: T
authors.lastname: Kumagai
authors.affiliation: Department of Health Services, Management and Policy, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maida Higashi, Fukuoka, 812-8582, Japan.
authors.forename: Akihito
authors.initials: A
authors.lastname: Hagihara
authors.affiliation: ASC Dermatology Service 1-3-2 Jindaijihigashi, Chofu, Tokyo, 182-0012, Japan.|Synergy Animal General Hospital Dermatology Service, 815 Ishigami Kawaguchi, Saitama, 333-0823, Japan.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Nagata
mesh_terms: D000818:Animals; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D017332:Cetirizine / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000628:therapy / Q000662:veterinary*; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D004311:Double-Blind Method; D005260:Female; D007778:Lactobacillus; D008297:Male; D019936:Probiotics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D017332:Cetirizine